Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer

被引:26
|
作者
Saito, Satoshi [1 ]
Abe, Takanori [1 ]
Kobayashi, Nao [1 ]
Aoshika, Tomomi [1 ]
Ryuno, Yasuhiro [1 ]
Igari, Mitsunobu [1 ]
Hirai, Ryuta [1 ]
Kumazaki, Yu [1 ]
Miura, Yu [2 ]
Kaira, Kyoichi [2 ]
Kagamu, Hiroshi [2 ]
Noda, Shin-ei [1 ]
Kato, Shingo [1 ]
机构
[1] Saitama Med Univ, Dept Radiat Oncol, Int Med Ctr, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
[2] Saitama Med Univ, Dept Resp Med, Int Med Ctr, Hidaka, Japan
关键词
Radiation pneumonitis; Dose-volume parameters; Durvalumab; Lung cancer; PHASE-III; CHEMORADIATION; CHEMOTHERAPY; RADIOTHERAPY; CISPLATIN;
D O I
10.1016/j.ctro.2020.05.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: We investigated the incidence and dose-volume relationships of radiation pneumonitis (RP) after concurrent chemoradiotherapy (CCRT) followed by durvalumab for locally advanced non-small-cell lung cancer (LA-NSCLC). Materials and methods: We retrospectively analyzed records of 36 patients with LA-NSCLC who underwent CCRT followed by durvalumab. Incidence of RP was analyzed for correlations with clinical factors and dose-volume parameters of lung in radiotherapy. Results: All patients received 60 Gy in 30 fractions of radiotherapy with concurrent chemotherapy. Over a median follow-up period of 7 months, incidence of grade >= 2 RP was 36% (including grade 3 RP: 5% and grade 5 RP: 3%). Age, sex, Brinkman index, and blood test results did not significantly differ between patients with grade >= 2 RP and grade >= 1 RP. Dose-volume parameters (lung volumes that received 5 Gy, 10 Gy, 20 Gy, 30 Gy, 40 Gy, 50 Gy, and mean lung dose) were significantly higher among patients with grade >= 2 RP compared with patients with grade >= 1 RP. Conclusion: Incidence of grade >= 2 RP was 36% after CCRT followed by durvalumab for LA-NSCLC, but did not significantly differ from those of patients treated with CCRT alone. Lung dose-volume parameters were significantly correlated with RP. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
引用
收藏
页码:85 / 88
页数:4
相关论文
共 50 条
  • [41] Assessment of radiation pneumonitis and predictive factors in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
    Gunnarsson, Kerstin
    Movik, Louise
    Pettersson, Niclas
    Back, Anna
    Nyman, Jan
    Hallqvist, Andreas
    ACTA ONCOLOGICA, 2024, 63 : 791 - 797
  • [42] Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer
    Kim, Myungsoo
    Lee, Jihae
    Ha, Boram
    Lee, Rena
    Lee, Kyung-Ja
    Suh, Hyun Suk
    RADIATION ONCOLOGY JOURNAL, 2011, 29 (03): : 181 - 190
  • [43] A DOSE-VOLUME ANALYSIS OF RADIATION PNEUMONITIS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH STEREOTACTIC BODY RADIATION THERAPY
    Barriger, R. Bryan
    Forquer, Jeffrey A.
    Brabham, Jeffrey G.
    Andolino, David L.
    Shapiro, Ronald H.
    Henderson, Mark A.
    Johnstone, Peter A. S.
    Fakiris, Achilles J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (01): : 457 - 462
  • [44] Functional dose-volume histograms for predicting radiation pneumonitis in locally advanced non-small cell lung cancer treated with late-course accelerated hyperfractionated radiotherapy
    Wang, Dongqing
    Li, Baosheng
    Wang, Zhongtang
    Zhu, Jian
    Sun, Hongfu
    Zhang, Jian
    Yin, Yong
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2011, 2 (05) : 1017 - 1022
  • [45] Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab
    Mouri, Atsuto
    Watanabe, Satoshi
    Tokito, Takaaki
    Nagai, Yoshiaki
    Saida, Yu
    Imai, Hisao
    Yamaguchi, Ou
    Kobayashi, Kunihiko
    Kaira, Kyoichi
    Kagamu, Hiroshi
    CANCERS, 2024, 16 (07)
  • [46] Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab
    Shintani, Takashi
    Kishi, Noriko
    Matsuo, Yukinori
    Ogura, Masakazu
    Mitsuyoshi, Takamasa
    Araki, Norio
    Fujii, Kota
    Okumura, Setsuko
    Nakamatsu, Kiyoshi
    Kishi, Takahiro
    Atsuta, Tomoko
    Sakamoto, Takashi
    Narabayashi, Masaru
    Ishida, Yuichi
    Sakamoto, Masato
    Fujishiro, Satsuki
    Katagiri, Tomohiro
    Kim, Young Hak
    Mizowaki, Takashi
    CLINICAL LUNG CANCER, 2021, 22 (05) : 401 - 410
  • [47] Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer
    Asakura, Hirofumi
    Hashimoto, Takayuki
    Zenda, Sadamoto
    Harada, Hideyuki
    Hirakawa, Koichi
    Mizumoto, Masashi
    Furutani, Kazuhisa
    Hironaka, Shuichi
    Fuji, Hiroshi
    Murayama, Shigeyuki
    Boku, Narikazu
    Nishimura, Tetsuo
    RADIOTHERAPY AND ONCOLOGY, 2010, 95 (02) : 240 - 244
  • [48] Concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: community hospital experience
    Rouvinov, K.
    Dudnik, J.
    Charkovski, T.
    Ariad, S.
    Lavrenkov, K.
    EJC SUPPLEMENTS, 2009, 7 (02): : 533 - 533
  • [49] Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer
    McCall, Neal S.
    Janopaul-Naylor, James R.
    McGinnis, H. Scott
    Kesarwala, Aparna H.
    Tian, Sibo
    Stokes, William A.
    Shelton, Joseph W.
    Steuer, Conor E.
    Carlisle, Jennifer W.
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    Bradley, Jeffrey D.
    Higgins, Kristin A.
    CANCER, 2023, 129 (23) : 3713 - 3723
  • [50] Radiation dose effect in locally advanced non-small cell lung cancer
    Kong, Feng-Ming
    Zhao, Jing
    Wang, Jingbo
    Faivre-Finn, Corrine
    JOURNAL OF THORACIC DISEASE, 2014, 6 (04) : 336 - 347